Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Text search

Sort by Default

Display 45 Products per page

bardoxolone methyl
Read More
Bardoxolone methyl (AbbVie/Kyowa Hakko Kirin), under development by the research-stage company Reata Pharmaceuticals, is a Phase III candidate in clinical trials for the treatment of pulmonary arterial hypertension.
October 29, 2018
Find out more
INOpulse
Read More
INOpulse (Bellerophon Therapeutics) is a drug-device combination being developed to deliver a continuous, pulsed dose of nitric oxide via intranasal inhalation.
October 29, 2018
Find out more
Aurora-GT
Read More
United Therapeutics is developing a gene therapy product called Aurora-GT (endothelial nitric oxide-synthase-enhanced endothelial progenitor cells)
October 29, 2018
Find out more
Tyvaso
Read More
United Therapeutics developed Tyvaso (treprostinil) as a follow-on product to Remodulin. As an inhaled formulation of treprostinil
October 29, 2018
Find out more
Revatio
Read More
Revatio (sildenafil), manufactured by Pfizer, is a selective inhibitor of the phosphodiesterase 5 (PDE5) enzyme, which enhances the effect of the endogenous vasodilator, nitric oxide (NO).
October 29, 2018
Find out more
Remodulin
Read More
Remodulin (treprostinil; United Therapeutics/Antigen/Mochida) is a prostaglandin analog that functions as a prostaglandin I2 (PGI2) receptor agonist.
October 29, 2018
Find out more
Opsumit
Read More
Actelion’s Opsumit (macitentan) is the follow-on product to the leading pulmonary arterial hypertension (PAH) therapy Tracleer.
October 29, 2018
Find out more
Adempas
Read More
Adempas (riociguat; Bayer/Merck & Co) is a first-in-class drug that activates soluble guanylyl cyclase (sGC), a key enzyme in nitric oxide-mediated vasodilation of vascular smooth muscle cells.
October 29, 2018
Find out more
Letairis
Read More
Letairis (ambrisentan; Gilead/AbbVie/GlaxoSmithKline) is a selective endothelin type A (ETA) receptor antagonist. Endothelin is a potent vasoconstrictor with mitogenic, hypertrophic, and pro-inflammatory.
October 29, 2018
Find out more
Uptravi
Read More
Uptravi (selexipag; Nippon Shinyaku/Actelion) is the first-in-class oral selective non-prostanoid prostaglandin I2 (PGI2) receptor agonist.
October 29, 2018
Find out more
Tracleer
Read More
Actelion’s Tracleer (bosentan) was the first oral therapy to be developed specifically for the treatment of pulmonary arterial hypertension (PAH).
October 29, 2018
Find out more
Adcirca
Read More
Launching after Revatio, Adcirca became the second-to-market PDE5 inhibitor upon its approval in major markets in 2009. Inhibiting the PDE5 enzyme enhances the effect of the endogenous vasodilator, nitric oxide (NO).
October 29, 2018
Find out more
Orenitram
Read More
United Therapeutics’ Orenitram (trepostinil) is the first-to-market oral formulation of a prostacyclin analog, and is a reformulation of the company’s intravenous prostacyclin analog Remodulin.
October 19, 2018
Find out more
Blincyto
Read More
Blincyto, produced in Chinese hamster ovary cells, is a bispecific T-cell engager that directs T-cells to target CD19-positive benign and malignant B-cells. It activates endogenous T-cells by connecting…
October 9, 2018
Find out more
Selinexor
Read More
Selinexor (Karyopharm/NPM Pharma) selectively inhibits the transport protein exportin-1 (XPO1), also called chromosome region maintenance-1.
October 9, 2018
Find out more
polatuzumab vedotin
Read More
Polatuzumab vedotin (Roche) is an antibody-drug conjugate (ADC) that combines a humanized immunoglobulin (Ig)-G1 monoclonal antibody (MAb) targeting human B-cell surface antigen cluster of differentiation (CD)79b and antimitotic agent monomethyl auristatin E (MMAE).
October 9, 2018
Find out more
MOR208
Read More
MorphoSys is positioning its cluster of differentiation (CD)19-targeted monoclonal antibody MOR208 in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients who are ineligible for high-dose chemotherapy and autologous stem cell transplant.
October 9, 2018
Find out more
Kinenza
Read More
Kinenza (enzastaurin) is an oral serine/threonine kinase inhibitor that suppresses signaling of protein kinase C (PKC)-beta to induce cell apoptosis, reduce cell proliferation, and suppress tumor-induced angiogenesis.
October 9, 2018
Find out more
MVA-BN RSV
Read More
MVA-BN RSV is a vaccine based on a recombinant MVA vector which expresses the RSV F and G glycoproteins, as well as the internal N and M2 proteins.
October 5, 2018
Find out more
GSK-3003891A
Read More
GSK-3003891A (GlaxoSmithKline) is an alum-adjuvanted respiratory syncytial virus (RSV) vaccine based on the prefusion form of the RSV fusion (F) protein. It is currently in Phase II development in the US and EU.
October 5, 2018
Find out more
ChAd155-RSV
Read More
ChAd155-RSV is a chimpanzee-derived adenovector vaccine encoding the F, N, and M2-1 proteins. The vaccine is in Phase II development for the prevention of serious lower respiratory tract disease caused by RSV in pediatric patients.
October 5, 2018
Find out more
MEDI8897
Read More
MEDI8897 is a human immunoglobulin G1 MAb derived from human B cells intended to provide protection against RSV infection.
October 5, 2018
Find out more
RSV F Vaccine
Read More
RSV F vaccine is an intramuscular recombinant nanoparticle vaccine comprising a highly purified post-fusion form of the RSV F protein that can be administered with or without an alum adjuvant.
October 5, 2018
Find out more
RSV preF vaccine
Read More
Pfizer’s RSV preF vaccine is based on the prefusion form of the RSV fusion protein, aided by the discovery of the crystal structure of key viral proteins by the National Institutes of Health.
October 5, 2018
Find out more
Ad26.RSV.preF
Read More
Ad26.RSV.preF, in development by Johnson & Johnson, is a replication-deficient vector vaccine that encodes a prefusion form of the RSV F protein.
October 5, 2018
Find out more
Live-attenuated RSV vaccines
Read More
In collaboration with the National Institute of Allergy and Infectious Diseases, AstraZeneca is developing a portfolio of three live-attenuated vaccines for the prevention of serious lower respiratory tract infections.
October 5, 2018
Find out more
Synagis
Read More
Synagis (palivizumab; AstraZeneca/AbbVie) is the global standard of care for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease.
October 5, 2018
Find out more
Alunbrig
Read More
Alunbrig (brigatinib; Takeda) is a dual anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.
September 8, 2018
Find out more
Symdeko
Read More
Vertex’s Symdeko ([tezacaftor + ivacaftor]) is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector compound
September 3, 2018
Find out more
Bronchitol
Read More
Bronchitol is an inhaled dry powder formulation of mannitol, a naturally occurring monosaccharide that also acts as a mucolytic agent.
September 3, 2018
Find out more
Cayston
Read More
Cayston is an inhalable formulation of the monobactam antibacterial aztreonam and was developed by Gilead.
September 3, 2018
Find out more
Kalydeco
Read More
Vertex’s Kalydeco is a CFTR potentiator that acts to increase chloride transport through CFTR.
September 3, 2018
Find out more
Quinsair
Read More
Quinsair is an inhaled formulation of the antibiotic levofloxacin that is approved in the EU for the management of chronic pulmonary infections
September 3, 2018
Find out more
Vertex triple combinations
Read More
Vertex is developing several triple combination regimens in order to further its cystic fibrosis portfolio with the best such regimen, combining a new CFTR corrector compound
September 3, 2018
Find out more
Arikayce
Read More
Arikayce is a formulation of the antibiotic amikacin that uses Insmed’s liposomal delivery system and is under development for the treatment of lung infections caused by NTM.
September 3, 2018
Find out more
Orkambi
Read More
Orkambi contains the combination of lumacaftor and ivacaftor, which has the dual mechanism of correcting and potentiating the function of CFTR protein, normalizing chloride conductance in patients with cystic fibrosis.
September 3, 2018
Find out more
Pulmozyme
Read More
Developed by Genentech, Pulmozyme is a recombinant form of human deoxyribonuclease I produced by genetically engineered Chinese hamster ovary cells
September 3, 2018
Find out more
Tobi/Tobi Podhaler
Read More
Tobi and the next-generation Tobi Podhaler are the gold-standard inhaled antibiotic treatments for cystic fibrosis patients.
September 3, 2018
Find out more
Gilotrif
Read More
Gilotrif is an orally administered TKI that irreversibly binds to EGFR/human epidermal growth factor receptor 1 (HER1), HER2, and HER4.
August 30, 2018
Find out more
Ensartinib
Read More
Ensartinib is a second-generation ALK inhibitor developed by Xcovery. In approximately 3–5% of all NSCLC patients, abnormal ALK configuration leads to the production of proteins that promote and maintain the malignant behavior of cancer cells (Soda et al., 2008; Solomon et al., 2013).
August 30, 2018
Find out more
Mekinist
Read More
Mekinist (trametinib; Novartis/Japan Tobacco) is a selective allosteric inhibitor of the MEK1 and MEK2 enzymes in the mitogen-activated protein kinase (MAPK) pathway.
August 30, 2018
Find out more
Dacomitinib
Read More
Dacomitinib is a small-molecule, irreversible inhibitor of HER1, HER2, and HER4, under development by Pfizer. Mutation or amplification of the HER gene is seen in several malignancies including…
August 30, 2018
Find out more
Zykadia
Read More
Zykadia (ceritinib; Novartis) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK).
August 30, 2018
Find out more
Iressa
Read More
Iressa (gefitinib; AstraZeneca) is a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase domain. The receptor is expressed on the cell surface of both normal and cancer cells.
August 30, 2018
Find out more
Seribantumab
Read More
Seribantumab (Merrimack Pharmaceuticals) is a monoclonal antibody directed against human epidermal growth factor receptor 3 (HER3).
August 30, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *